Trials / Completed
CompletedNCT04952064
An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke
Ganglioside GM1 in Acute Ischemic Stroke: a Prospective, Randomized, Blinded Assessment of Endpoints, and Multicenter Exploratory Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- General Hospital of Shenyang Military Region · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the efficacy and safety of higher doses of monosialoganglioside GM1 injection in the treatment of patients with acute ischemic stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Monosialoganglioside GM1 | Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days |
Timeline
- Start date
- 2021-07-28
- Primary completion
- 2022-07-18
- Completion
- 2022-07-18
- First posted
- 2021-07-07
- Last updated
- 2022-09-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04952064. Inclusion in this directory is not an endorsement.